Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Adrienne M. Gilligan"'
Publikováno v:
Journal of Health Economics and Outcomes Research (2021)
**Background:** Despite the availability of new treatments, multiple myeloma (MM) is an incurable cancer with nearly all patients relapsing and undergoing multiple lines of treatment. Performing head-to-head comparisons of all treatment options is no
Externí odkaz:
https://doaj.org/article/dc14d2de37f34e349027bb526b50914a
Autor:
Travis A Motley, Adrienne M Gilligan, Darrell L Lange, Curtis R Waycaster, Jaime E Dickerson Jr
Publikováno v:
Journal of Foot and Ankle Research, Vol 8, Iss 1, Pp n/a-n/a (2015)
Abstract Background Approximately 10%–15% of people with diabetes develop at least one foot ulcer during their lifetime. Treatment of diabetic foot ulcers (DFUs) represents a significant economic burden. Enzymatic debridement with clostridial colla
Externí odkaz:
https://doaj.org/article/45ffb22e414942e39d677e949370e4a1
Autor:
Adrienne M Gilligan, Chen-Yen Lin, Orin Goldblum, Mwangi J Murage, Oth Tran, Russel Burge, Abrar A. Qureshi
Publikováno v:
Journal of Dermatological Treatment. 32:56-63
Objectives: To describe ixekizumab treatment patterns, all-cause healthcare utilization, and costs among psoriasis patients.Methods: Adults diagnosed with psoriasis having ≥1 ixekizumab claim were ...
Autor:
Cheng Wang, Caroline Henriques, Adrienne M Gilligan, Amy Sainski-Nguyen, Jessica Franchino-Elder, Briain O Hartaigh, Xue Song
Publikováno v:
Journal of Cardiology and Cardiovascular Sciences. 3:36-46
Autor:
Adrienne M Gilligan, Brooke Harrow, Paul Juneau, Karin Travers, Mohan Bala, Brian Davis, Paula Smith
Publikováno v:
Journal of Clinical Pathways. 5:40-48
Autor:
Giovanni Grignani, Albiruni Ryan Abdul Razak, Mrinal M. Gounder, Neeta Somaiah, Andrew J. Wagner, Michael Kauffman, Bruno Vincenzi, Scott M. Schuetze, Javier Martin-Broto, Richard F. Riedel, Jatin P. Shah, Steven Attia, Bartosz Chmielowski, Robin L. Jones, Sant P. Chawla, Hoyee Leong, Adrienne M Gilligan, Sharon Shacham, Xiwen Ma
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
instname
[Objective] Compare health-related quality of life (HRQoL) of selinexor versus placebo in patients with dedifferentiated liposarcoma.
[Materials & methods] HRQoL was assessed at baseline and day 1 of each cycle using the European Organization fo
[Materials & methods] HRQoL was assessed at baseline and day 1 of each cycle using the European Organization fo
Autor:
Cheng Wang, Kathleen Wilson, Jessica Franchino-Elder, Xue Song, Adrienne M Gilligan, Stephen Sander, Caroline Henriques, Amy Sainski-Nguyen, David M. Smith
Publikováno v:
Expert Review of Pharmacoeconomics & Outcomes Research. 19:203-212
This is one of the first head-to-head real-world evidence studies comparing stroke-related and bleed-related healthcare and resource utilization (HCRU) and costs among non-valvular atrial fibrillation (NVAF) patients initiating oral anticoagulants.Ad
Autor:
Adrienne M Gilligan, Marissa J Carter, Curtis Waycaster, Caroline E. Fife, Elizabeth S. Mearns, Catherine T Milne
Publikováno v:
Journal of Comparative Effectiveness Research. 7:149-165
Chronic dermal ulcers affect approximately 2.4–4.5 million people in the USA and are associated with loss of function, decreased quality of life and significant economic burden. Debridement is a critical component of wound care involving removal of
Autor:
Gregory L Price, Yajun Emily Zhu, Yu-Jing Huang, Gregory A. Vidal, Angelo DeLuca, Emily Nash Smyth, Lee S. Schwartzberg, Sarah Rybowski, Gebra Cuyun Carter, Kim Saverno, Adrienne M Gilligan
Publikováno v:
Clinical Breast Cancer. 21:317-328.e7
Background This study explored the impact of multiple prognostic factors on patient overall survival (OS) and real-world progression-free survival (rwPFS) for patients with hormone receptor-positive (HR+)/human epidermal growth factor 2 negative (HER
Autor:
Cheng Wang, Amy Sainski-Nguyen, Caroline Henriques, Adrienne M Gilligan, David M. Smith, Stephen Sander, Kathleen Wilson, Jessica Franchino-Elder, Xue Song
Publikováno v:
Current Medical Research and Opinion. 34:285-295
Compare costs and healthcare resource utilization (HCRU) among newly-diagnosed non-valvular atrial fibrillation (NVAF) patients newly treated with dabigatran vs apixaban, rivaroxaban, or warfarin.Newly-diagnosed adult NVAF patients initiating dabigat